ArticleCurrent medical science2025
Impact of Statin Therapy on Long-Term Survival of Patients with Chronic Kidney Disease but Without Atherosclerotic Cardiovascular Disease: Insights from the American MIMIC-IV and Chinese CIN-II Databases.
Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
objectivePatients with chronic kidney disease (CKD) without atherosclerotic cardiovascular disease (ASCVD) have high mortality rates. Guidelines indicate that statin therapy can reduce mortality in CKD patients with ASCVD; however, its benefits for CKD patients without ASCVD remain unclear. This study examined the survival benefits of statin therapy in CKD patients without ASCVD in American and Chinese cohorts.
methodsA total of 4369 patients diagnosed with CKD without concurrent ASCVD were included from the American Medical Information Mart for Intensive Care (MIMIC)-IV database (n = 1786) and the Chinese Multicenter Registry Cohort for Cardiorenal Improvement II (CIN-II, n = 2583). Participants were grouped by statin use (treated and untreated). The two groups were compared for key indicators, including: (1) statin use rate; (2) 4-year all-cause mortality; (3) 4-year cardiovascular mortality (assessed in the CIN-II cohort). Statistical analyses included Kaplan-Meier survival curves (with log-rank test for group differences) and Cox proportional hazard models (adjusted for confounders) to estimate the association between statin use and mortality.
resultsIn the MIMIC-IV cohort, 37.6% of CKD patients received statins, with a 4-year all-cause mortality of 36.3%. After adjustment, statin therapy was associated with lower all-cause mortality (adjusted hazard ratio [aHR]: 0.61; 95% confidence interval [CI]: 0.51-0.72; P < 0.001). In the CIN-II cohort, 33.9% of patients received statins; the 4-year all-cause and cardiovascular mortalities were 10.5% and 5.3%, respectively. Adjusted analyses demonstrated that statin therapy reduced both all-cause mortality (aHR: 0.74; 95% CI: 0.56-0.99; P = 0.037) and cardiovascular mortality (aHR: 0.64; 95% CI: 0.42-0.97; P = 0.031).
conclusionApproximately two-thirds of CKD patients without ASCVD in both the American (MIMIC-IV) and Chinese (CIN-II) cohorts did not receive statins. However, statin therapy reduced 4-year all-cause mortality by 26% and 39% in the American and Chinese cohorts, respectively. These findings highlight a clear survival benefit of statin therapy and warrant future randomized controlled trials.
Indexed as
Identifiers
41296254What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.